Evidence map›Paper›PMID 39299543›Full record

ArticleContemporary clinical trials2024

Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST): Design and methods of a prospective, randomized, controlled trial.

Jacob A Quaytman, Natalie L David, Sharini Venugopal, Tânia Amorim, Britney Beatrice, Frederico G S Toledo, Rachel G Miller, Matthew L Steinhauser, Pouneh K Fazeli

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05722873 (The Effects of Fasting on Reprogramming of Lipid Metabolism and Bone Metabolism), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05722873 narecruitingnot on this map

The Effects of Fasting on Reprogramming of Lipid Metabolism and Bone Metabolism

TypeinterventionalSponsorUniversity of PittsburghRan2023 to 2028Enrolled90ConditionsNormal and Overweight Individuals at High-risk of DiabetesArmsFasting arm, Weight maintenance, Counseling
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jacob A QuaytmanDivision of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Natalie L DavidDivision of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Center for Human Integrative Physiology, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Sharini VenugopalDivision of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Tânia AmorimDivision of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Center for Human Integrative Physiology, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Britney BeatriceDepartment of Sports Medicine and Nutrition, University of Pittsburgh School of Health and Rehabilitation Sciences, Pittsburgh, PA 15260, USA.
Frederico G S ToledoDivision of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Rachel G MillerDepartment of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Matthew L SteinhauserCenter for Human Integrative Physiology, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Division of Cardiovascular Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Electronic address: msteinhauser@pitt.edu.
Pouneh K FazeliDivision of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Center for Human Integrative Physiology, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Neuroendocrinology Unit, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Electronic address: pkfazeli@pitt.edu.

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
T32 Research Training in Diabetes and EndocrinologyT32DK007052 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROBERT M O'DOHERTY · 1986 to 2026
$6.3M
Beneficial reprogramming of lipid metabolism with intermittent fastingR01DK133578 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Pouneh Khadejeh Fazeli, Matthew Steinhauser · 2023 to 2026
$2.7M
NCATS NIH HHS UL1 TR001857NIDDK NIH HHS R01 DK133578NIDDK NIH HHS T32 DK007052
6 · The paper itself

Abstract

backgroundCaloric restriction prolongs lifespan in model organisms and improves metrics of aging-related diseases in humans, but daily compliance is challenging. Intermittent fasting improves metrics of lipid and glucose metabolism in the setting of weight loss but whether these metrics are improved independent of weight loss is not known.

methodsWe seek to address this gap with IFAST, a single-center, three-arm, prospective, randomized, controlled clinical trial. Eligible study participants are adults with no chronic medical conditions beyond prediabetes or overweight but who are at high risk for type 2 diabetes mellitus (T2D), defined as having a history of gestational diabetes or a first-degree relative with T2D. Participants will be randomized in a 1:2:2 schema to either a control group, a fasting group, or a fasting/weight maintenance group. The fasting groups will complete a 24-h fast one day per week for 12 weeks. The key mechanistic endpoint is change in triglyceride composition (defined by carbon content and degree of saturation) as measured by longitudinal metabolomics. The key safety endpoint is percent change from baseline in bone volume fraction (BV/TV; high-resolution peripheral quantitative CT) at the radius in the fasting group. Secondary endpoints include measures of insulin sensitivity (hyperinsulinemic-euglycemic clamp), clinical lipid profiling, systemic inflammation markers, hunger assessment, bone density, and bone microarchitecture with high-resolution peripheral quantitative CT.

conclusionIFAST will investigate intrinsic metabolic benefits of intermittent fasting beyond weight loss.

trial registrationClinicalTrials.gov ID NCT05722873.

Indexed as

Caloric RestrictionDiabetes Mellitus, Type 2FastingTriglyceridesAdultFemaleHumansIntermittent FastingMaleMetabolic ReprogrammingMiddle AgedProspective StudiesRandomized Controlled Trials as TopicWeight LossTriglyceridesBone metabolismInsulin resistanceIntermittent fastingRandomized controlled trialTriglyceridesWeight loss

Identifiers

PMID39299543
PMCPMC11625453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.